Related Experiment Videos

Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to

T Nakamura1, C Ushiyama, Y Suzuki

  • 1Department of Medicine, Misato Junshin Hospital, Saitama, Japan.

The Journal of Hospital Infection
|December 24, 2002
PubMed

Insights

Combination therapy using polymyxin B-immobilized fiber (PMX-F) and teicoplanin significantly improves survival rates in patients with methicillin-resistant Staphylococcus aureus (MRSA) sepsis.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Pharmacology

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) sepsis poses a significant threat with high mortality rates.
  • Conventional therapies for MRSA sepsis have limitations in improving patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy of polymyxin B-immobilized fiber (PMX-F) hemoperfusion, teicoplanin, and their combination in treating MRSA sepsis.
  • To compare the effectiveness of these treatments against conventional therapy.

Main Methods:

  • A randomized study involving 60 patients with MRSA sepsis assigned to four groups: PMX-F, teicoplanin, combination therapy, and conventional therapy.
  • PMX-F treatment was administered twice, while teicoplanin was given intravenously.
  • Plasma endotoxin levels were measured, and survival rates and duration of hospital stay were recorded.

Main Results:

  • Combination therapy (PMX-F and teicoplanin) resulted in a significantly higher survival rate (90%) compared to PMX-F alone (53%), teicoplanin alone (47%), and conventional therapy (20%).
  • Plasma endotoxin levels were reduced in patients treated with PMX-F (groups A and C).
  • The combination therapy group also showed a reduced mean duration of hospital stay (28 days).

Conclusions:

  • Combination therapy with PMX-F and teicoplanin is highly effective in treating MRSA sepsis.
  • This combined approach offers a promising strategy to improve survival and reduce hospital stay in patients with MRSA sepsis.

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...